ঔষধ তালিকায় ফিরুন
ডাক্তারের পরামর্শ
এই ওষুধটি সেবনের আগে অভিজ্ঞ ডাক্তারের পরামর্শ নিন।
Lacosamide is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Lacosamide is indicated for adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
It is proposed that lacosamide's inhibition of sodium channels is responsible for analgesia. Lacosamide may be selective for inhibiting depolarized neurons rather than neurons with normal resting potentials. Pain and nociceptor hyperexcitability are associated with neural membrane depolarization. Lacosamide binds to collapsin response mediator protein-2 (CRMP-2), a phosphoprotein which is expressed primarily in the nervous system and is involved in neuronal differentiation and control of axonal outgrowth. The role CRMP-2 of binding in seizure control is hasn't been elucidated.The precise mechanism by which Lacosamide exerts its anti-epileptic effects in humans remains to be fully elucidated. In vitro electrophysiological studies have shown that Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.
